

A Randomized, Double-Blind, Single-Dose Study Comparing With Bevacizumab (Avastin®) in Chinese Healthy Male

Frontiers in Pharmacology

12, 694375

DOI: [10.3389/fphar.2021.694375](https://doi.org/10.3389/fphar.2021.694375)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Comparative Pharmacokinetics, Safety, and Immunogenicity Study of the Prefilled Syringe and Lyophilized Formulation of a Recombinant Human Tumor Necrosis Factor- α Receptor II:IgG Fc Fusion Protein in Healthy Chinese Male Subjects. <i>Clinical Pharmacology in Drug Development</i> , 2022, , .	0.8	0